Indications for: Nefazodone
≥18 years: initially 200mg daily in 2 divided doses; increase in increments of 100–200mg/day in 2 divided doses at 1-week intervals; range 300–600mg/day. Debilitated: initially 100mg daily in 2 divided doses.
<18 years: not recommended.
Concomitant MAOIs, cisapride, carbamazepine; triazolam (see Interactions). Active liver disease. Elevated baseline serum transaminases. History of nefazodone-associated liver dysfunction.
Monitor for liver dysfunction; discontinue if signs of liver disease occur (eg, AST or ALT ≥ 3XULN). Cardio- or cerebrovascular disease. Predisposition to hypotension (eg, dehydration, hypovolemia). Mania/hypomania. Suicidal patients. Seizure disorders. Hepatic cirrhosis. Discontinue and reevaluate if priapism occurs. ECT. Reevaluate periodically. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers.
Allow 14 days after discontinuing an MAOI before starting nefazodone; allow 7 days after discontinuing nefazodone before starting an MAOI. Avoid alcohol. Avoid concomitant triazolam (esp. in elderly); if used, reduce concomitant triazolam dose by 75%. Reduce concomitant alprazolam dose by 50%. Caution with antihypertensives, diuretics, other CNS-active drugs, oral anticoagulants, oral hypoglycemics, aspirin, other highly protein-bound drugs, drugs metabolized by CYP3A4. Risk of rhabdomyolysis with statins metabolized by CYP3A4 (eg, simvastatin, lovastatin, atorvastatin). May potentiate buspirone, haloperidol (reduce dose); cyclosporine, tacrolimus, digoxin (monitor). Discontinue before general anesthesia.
Headache, nausea, dizziness, insomnia, asthenia, agitation, somnolence, dry mouth, constipation, blurred or abnormal vision, confusion, postural hypotension, priapism, others; rare: hepatic failure.
Formerly known under the brand name Serzone.